Tapemark, a world-leading expert in transdermal patch formulation, design, development and manufacturing, and Biotts, a Polish biotechnological company that develops proprietary drug delivery technologies and drug formulas, announce a strategic partnership to commercialize MacroPerm™.
MacroPerm™ is a new large-molecule transdermal technology designed to transport API (Active Pharmaceutical Ingredients) through the skin. The solution will accelerate the development of new solutions to solve challenging health issues for patients who can benefit from transdermal treatment.
“We believe Biotts’ innovation in large molecule permeation, when paired with Tapemark’s expertise in transdermal technology, will result in new and exciting products for pharma clients. This is something that will ultimately help patients around the world,” said Beau Garrett, Tapemark Sr. Vice President and COO.
The innovative benefits of the MacroPerm™ patent protected permeation system for transdermal administration include:
- More precise development programs given targeted formulation
- Therapeutic delivery of larger molecules previously not deliverable without mechanical assistance
- Patent protection for novel NDA and 505b2 assets
- Less gastrointestinal side effects for patients compared to oral drug administration
- Increased bioavailability of the active pharmaceutical
- Larger therapeutic window of the active pharmaceutical
- Significantly improved patient compliance.
“We are extremely enthusiastic about our strategic partnership with Tapemark, which underlines our commitment to creating brand new transdermal products in their class,” said Paweł Biernat, Ph.D., CEO of Biotts Inc. “Biotts has developed patented transdermal technology to expand drug delivery options to patients, with plans to further develop innovative products in collaboration with Tapemark.”
“Increasing bioavailability while mitigating side effects is the ‘Holy Grail’ of many research teams. The development of deep penetrating transdermal systems, selectively acting on pathologically changed tissues allows for a stronger therapeutic effect, while significantly increasing patient comfort and reducing the costs of treatment,” said Konrad Krajewski, Vice President at Biotts Inc.
In the coming years, Tapemark and Biotts fully expect to be delivering molecules at therapeutic levels that were previously not thought possible given current technology.
To learn more about MacroPerm™ visit Tapemark.com/macroperm.
Tapemark is a world leading complex drug delivery system CDMO innovating in the formulation, development, scale-up and commercial manufacturing of transdermal, oral thin film and unit dose semi-solid drugs. With nearly 70 years of experience, Tapemark has worked with hundreds of clients from around the globe, proudly partnering with pharmaceutical innovators of every shape and size.
Biotts S.A. is a Polish biotechnological company that develops proprietary drug delivery technologies and drug formulas in the field of oncology, dermatology and autoimmune diseases. With more than 30 years of experience, Biotts’s Research and Development team is able to effectively create proprietary medicines, solve complex technological problems, and create unique solutions to help people all over the world.
Tapemark Media Contact Info
Public Relations Specialist at Vye
Biotts Media Contact Info